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This manuscript describes a protocol at the University of Kentucky that allows a
translational research team to collect human myocardium that can be used for
biological research. We have gained a great deal of practical experience since
we started this protocol in 2008, and we hope that other groups might be able to
learn from our endeavors. To date, we have procured ~4000 samples from ~230
patients. The tissue that we collect comes from organ donors and from patients
who are receiving a heart transplant or a ventricular assist device because they
have heart failure. We begin our manuscript by describing the importance of
human samples in cardiac research. Subsequently, we describe the process for
obtaining consent from patients, the cost of running the protocol, and some of the
issues and practical difficulties that we have encountered. We conclude with
some suggestions for other researchers who may be considering starting a
similar protocol.
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Introduction
Heart failure is a clinical syndrome that manifests when there are structural and
functional impairments to the heart that alters its ability to pump (1). The etiology
of heart failure is complex but individuals who suffer from cardiovascular
diseases including cardiomyopathy, myocarditis, hypertension, coronary
atherosclerosis, and valvular and congenital heart malformations, are at
increased risk (2). Currently, more than 23 million people worldwide suffer from
the disease, which has a mortality rate of ~50% within the first five years of
diagnosis (3). In the United States alone, heart failure affects ~6 million
individuals with an estimated 650,000 new cases diagnosed annually. Taken
together, heart failure costs the US healthcare system ~40 billion dollars a year
(1, 4-6).
Despite intensive efforts, treatment options for patients who have advanced heart
failure remain limited. Research that identifies mechanisms that contribute to
impaired ventricular function can offer new hope to patients by supporting the
development of better therapies. Many significant insights have been obtained to
date by studying mice and rats. However, there are significant differences
between the cardiac biology of rodents and humans, including (but not limited to)
heart rate, oxygen consumption, and adrenergic receptor ratios (7, 8). Large
animal models, such as dogs, pigs, and sheep, more closely approximate human
cardiac function but also have limitations. For example, very few academic labs
can afford to maintain dogs and pigs for research.
The aim of this manuscript is to describe a collection protocol that we have
developed at the University of Kentucky to study cardiac samples from patients
who are suffering from heart failure and research donors with non-failing hearts.
It has taken us several years to develop and refine this protocol, and we would
like to share what we have learned with the research community. We hope that
reading about our experience will encourage other groups to start similar
collection protocols. Human biospecimens cannot fully replace animal models in
cardiovascular research. However, we think that many groups might be able to
use human samples to accelerate their research and increase the translational
significance of their work.

Informed Consent
Our program is approved by the University of Kentucky’s Institutional Review
Board (IRB) and is an opt-in consent program focusing on advanced heat failure.
We aim to approach all patients who have been listed for heart transplant or will
be implanted with a Ventricular Assist Device (VAD) and ask for their consent to
use samples of their tissue for research. All of the samples that we procure are
removed as part of normal clinical care and would be discarded if they were not
saved for research. We do not currently perform pediatric heart transplants or
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implant VADs into children at the University of Kentucky so all of our patients are
18 years or older.
Consents are normally obtained by a member of the patient’s clinical team. We
have found that it is simplest to obtain consent for potential heart transplant
patients when they are being listed for transplant. Patients who will be receiving
VADs are typically consented for research when they are being consented for the
VAD implant. We explain that the samples we hope to procure will be discarded if
they are not used for research and describe the potential risks of joining the
study, which mainly relate to a potential loss of confidentiality if data are
accidentally disclosed. We have sought consent from hundreds of patients since
2008 and virtually all of them have agreed to participate. Many of them are
surprised that this sort of research is not more common. Patients often tell their
team that they want to support the research because it might prevent somebody
else from having to experience similar clinical problems.
Our protocol also allows us to collect myocardial samples from organ donors
when the heart will not be used for transplant. For example, we might be able to
acquire hearts that come from donors who have hepatitis or atherosclerosis. At
the University of Kentucky, researchers and heart failure clinicians do not
typically interact with the families of organ donors. Instead, the consent to donate
samples is obtained by a member of the Organ Procurement Organization
(OPO). Our OPO is Kentucky Organ Donor Affiliates (KODA) who typically ask
the family of the donor for permission to (a) use organs for transplant, and (b)
use organs for research if they cannot be used for transplant. If the family of the
donor agrees to both of these requests, the OPO passes that information on to a
member of our research team.
The protocol also allows us to extract data from the medical records of the
patients who donated samples. We can use these data to link our research
findings to specific medical conditions. We updated our protocol in 2013 so that
we could share samples and the associated de-identified medical data (for
example, age, diagnosis, body mass index, ejection fraction, diabetic status, etc.)
with researchers at other institutions. This increases the impact of our work and
further accelerates the research.
It is important to note that only researchers who are listed on the IRB protocol at
the University of Kentucky are able to link specimens to specific people.
Scientists at other institutions are never given access to the 18 types of data that
are defined as Protected Health Information (PHI) by the Health Insurance
Portability and Accountability Act (HIPAA). These data fields include names,
addresses, and medical record numbers that are linked to a specific person.
At the moment, we have chosen not to return specific research results to the
patients who donated samples. We explain this when we seek consent and we
have adopted this approach because our current experiments won’t impact the
immediate treatment plan. Returning every experimental result to each patient
might increase anxiety without having a positive effect. We recognize that this is
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a complex area and might choose to revise the policy in the future as guidelines
evolve.

Timeline for tissue procurement
Our procurement protocol is design to optimize the quality of the samples that we
collect for research. The main goals are (a) to keep the heart or tissue samples
cold as soon as they are removed from the patient or organ donor, and (b) to
minimize the time before the samples are used for experiments with living cells or
frozen in liquid nitrogen. Typically, samples that are frozen are placed in
cryogenic vials and dropped into liquid nitrogen within ~30 minutes of being
removed from the patient. Our experimental data show that this interval is short
enough to preserve the integrity of sarcomeric proteins and mRNA (9).
As shown in Fig.1, the timeline for procurement starts when the circulating nurse
who will be managing the operating room during the cardiac procedure calls a
dedicated mobile phone. (Scientists in our lab take turns carrying this phone,
which is answered 24 hours per day.) This first call typically occurs 2 to 3 hours
before samples will become available so the scientist has time to travel to the
university if they are not already there, and to prepare their equipment.
The circulating nurse calls the mobile phone a second time when the surgeon
makes the first incision. This is the signal for the scientist to leave the lab and to
walk to the clinical area. After changing into surgical scrubs, the scientist enters
the operating room and notifies the circulating nurse that they are available to
receive samples. If the operating room is very busy, the scientist may choose to
wait outside. Typically though, the scientist waits in the back of the operating
room for 5 to 60 minutes until the tissue is excised. The surgeon or scrub nurse
hands the relevant samples to the circulating nurse who passes the tissue
directly to the scientist. The scientist immediately places the tissue in a plastic
container filled with cold saline slush, and then inserts that container into an
insulated box. He/she then carries the insulated box back to the research lab (3
to 5 minute walk).

Fig. 1. Timeline for tissue procurement
Once back in the lab, the scientist removes the cardiac tissue from the insulated
box and begins to dissect the samples. If they are going to attempt experiments
with living cells, the scientist may isolate trabeculae or through-wall ventricular
wedge sections. However, the main goal is to freeze samples for subsequent
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analysis. As shown in Table 1, we aim to isolate sections from three transmural
regions (sub-endocardial, mid-myocardial, and sub-epicardial) of tissue cores
procured during VAD implants and from the left ventricular wall of explanted
hearts. When possible, we also try to produce additional samples from the
septum, the right ventricle, and both atria.
Tissue samples are cut into small blocks weighing 500 to 1000 mg and placed
into pre-labeled 2 ml cryogenic tubes. These are then dropped into liquid nitrogen
where the tissue freezes rapidly. After all of the samples have been frozen, they
are placed in freezer boxes, and transferred to large tanks where they are
maintained in the vapor phase of liquid nitrogen for long-term storage.
Table 1. Procurement procedure for heart transplant and LVAD samples
Heart Transplant
LVAD
Location of
 Left ventricular free wall
 Through-wall core removed
samples
from the left ventricular
collected
apex before the VAD is
 Right ventricular free wall
implanted
 Atria

Processing

Storage of
samples



Septum



Cut tissue samples that 
are ~5 x 5 cm

Split core into transmural
regions if possible



Split
left
ventricular 
samples
into
subendocardial,
midmyocardial,
and
subepicardial regions (Fig. 2a)

Further dissect into a few (1
to 3) samples (each ~500
mg) and place in cryogenic
vials



Obtain 6 to 10 samples
(each 500~1000 mg) for
each region and place in
cryogenic vials



Flash freeze samples in liquid nitrogen



Place frozen samples in storage box (Fig. 2b)



Place box in cryogenic tank for storage in the vapor phase of
liquid nitrogen (Fig. 2c)
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Data management
De-identification
Only scientists and clinicians who are listed on our IRB protocol are allowed to
know the identities of the people who donated cardiac tissue. To preserve
privacy, we therefore allocate a unique randomized identifier (which we term a
hashcode) to each tissue procurement procedure. The vials containing the tissue
samples are only labeled with this hashcode and the region of the heart that the
sample was procured from. This allows us to share samples with other
researchers without compromising the identity of the patient or donor.

Fig. 2. Tissue dissection and storage.
Fig. 2a. ~5 cm x 5 cm piece of tissue from the LV annotated to show how
the samples are separated into three transmural regions.
Fig. 2b. Storage vials with hashcode and storage box.
Fig. 2c. Cryogenic tanks that store samples in the vapor phase of liquid
nitrogen
Each hashcode consists of 5 characters which are either digits (0 to 9) or letters
in the range A to F (for example, 34F2A). We generated ~1,000,000 such codes
at the beginning of our study by creating a random permutation of the integers
from 1 to 216 and then converting that list to hexadecimal. Hashcodes are
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selected from the random list in turn so there is no practical way for an outside
party to link the hashcode to a specific person, or even to an approximate
procurement date.

Inventory
As described, sample vials are labeled only with the hashcode for the
procurement and the region of the heart that the tissue was acquired from (for
example, A231E, Right Ventricle). Vials are placed in storage boxes that have 81
positions (labeled from A1 to I9). These boxes are in turn placed in one of 144
slots in our 3 cryogenic storage tanks (Fig. 2c).
We record the hashcode, cardiac region, box position, slot number, and sample
status (for example, available, or previously thawed) for each sample in Excel
and use the resulting computer file to manage our inventory. We have several
computer programs (written in MATLAB) that allow us to select samples and/or
generate reports from the Excel file.

Clinical data
We use REDCap (Research Electronic Data Capture) software (10-13) to store
and manage the clinical data that we collect for each patient and organ donor.
This software is a secure, web-based database that is HIPAA compliant and
approved by our IRB. One of the advantages of REDCap is that it allows us to
restrict access to patient identifiers. Thus researchers who are not listed on our
IRB can access the database to download clinical data but cannot obtain
information about the identity of the patient or donor. This simplifies our logistics
and makes it easier to manage our protocol.

Experimental techniques
We use the myocardial samples that we acquire to investigate cellular and
molecular mechanisms that contribute to heart failure. We can perform
experiments immediately after we procure the samples (fresh tissue) or using
samples that have been previously frozen. Our laboratory specializes in
experiments assessing contractile properties but we have also analyzed the
samples using numerous histological and biochemical techniques.
The techniques that we have implemented using human samples include:
Fresh tissue:


Mechanical studies
o

Single cells –ventricular myocytes are loaded with Fura-2 (a dye
that indicates the intracellular Ca2+ concentration) and electrically
stimulated. We use a photomultiplier and a high-speed camera to
measure the Ca2+ transients and shortening profiles as the cells
undergo unloaded twitch contractions.
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o

Trabeculae – intact trabeculae are attached between a force
transducer and motor. We measure contractile force during
electrically evoked twitch contractions and a range of parameters
relating to myocardial relaxation.

Frozen tissue:


Mechanical studies
o

Permeabilized single cells – single cells are chemically
permeabilized using triton and attached between a force
transducer and a motor. We typically measure contractile force,
calcium sensitivity (pCa50), and the rate of tension recovery (ktr) at
different levels of Ca2+ activation. These cells do not have large
amounts of extracellular matrix so their passive stiffness is
primarily due to titin molecules.

o

Permeabilized multicellular preparations – larger preparations
(typically ~600 x 120 x 120 µm) are chemically permeabilized and
attached between a force transducer and a motor and analyzed
using similar techniques to those described for single
permeabilized cells above. The passive stiffness of these
preparations reflects titin molecules and an additional contribution
from extracellular matrix proteins.



Histology



Microarrays to measure mRNA and microRNA levels



Gel electrophoresis



Collagen analysis



PCR

Personnel and financial costs
Some of the clinical staff take on additional responsibilities to help us procure
cardiac samples for research. We list some of these responsibilities along with an
estimate of the time involved in Table 2. Table 3 shows the responsibilities and
time commitment for research staff. Finally, Table 4 provides estimates of the
financial costs. We are providing these data because we think that they may be
useful to readers who are interested in starting their own procurement system.
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Table 2 - Clinical staff
Title
Number of Responsibilities for this Time
personnel
program
involved
Transplant
surgeons

4

Agree to allow samples to Minimal
be used for research

Transplant
and
VAD
coordinators

3

Obtain patient consents

Operating
room
nursing staff

Many

20
minutes
patient

per

Call research scientist, 10
minutes
hand excised heart to procurement
scientist

per

Table 3 - Research staff
Title

Scientists

Number of
personnel
involved
3

Responsibilities

Time

Procure samples

Up to 4 hours waiting per
heart plus ~1 hour to
isolate samples, clean
the procedure areas, and
restock supplies.

IRB manager

1

Maintain IRB protocol, 20 hours per year
manage changes in
personnel

Clinical data
manager

1

Maintain
clinical 40 hours per year plus 2
database, extract data hours per patient
from medical records

Sample
management

1

Manage
specimen 6 hours per week
inventory,
maintain
cryogenic tanks
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Item

Cost

Yearly estimate

Sample vials

$180 per case

$540
(~3 cases per year)

Liquid nitrogen

$38 per month

$456

Phone

$50 per month

$600

Cryogenic tanks

$5,000
per
tank
(holds ~1600 vials)

Table 4 – Cost

Problems and weaknesses
One of the challenges that we have faced with this protocol is ensuring that
scientists are available 24/7 to collect the samples from the operating room. This
is a particular problem for heart transplants because these procedures can occur
at any time of the day or night. (Most VAD placements take place during weekday mornings when the scientists are typically at work already.) Having a large
team of scientists available to procure samples places less burden on each
individual and makes it easier to provide 24/7 cover. However, having a team
that is too large is also problematic. For example, if each scientist only performs
a few procedures it can be difficult to ensure that samples are dissected
consistently. A large team also makes it harder for each scientist to build their
working relationship with the clinical staff in the operating room. This relationship
is important because the clinical staff need to be confident that the scientist can
collect the samples without compromising any aspect of the surgery. We have
found that the system works best at our institution with a team of ~4 scientists.
Another challenge is obtaining non-failing hearts. Data provided by our local
organ procurement agency (Kentucky Organ Donor Affiliates) show that thoracic
organs are donated roughly once per week at the University of Kentucky. Since
many hearts are not suitable for transplant, it might be possible to obtain nonfailing hearts once every 2 or 3 weeks. In practice, we have collected an average
of about two per year. The main problem has been that our clinical collaborators
are not normally involved in organ procurements when the heart is not being
used for transplant. Thus, we don’t learn about organ procurements until after
they have occurred. We are trying to improve our performance in this area and
have recently developed stronger interactions with the organ donation team at
our institution. We hope that this new development will help us to accelerate the
rate at which we procure non-failing hearts.
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One of the main interests of our lab is understanding how regional and
transmural patterns of contraction influence ventricular function. To learn more
about these effects, we measure the biochemical and contractile properties of
cells from different parts of the heart. It is not yet clear how these properties are
distributed, which makes it difficult to know the optimal way to dissect the
samples. The practical approach that we have taken for left ventricular tissue is
to separate the free wall into thirds (Fig. 2a). This is probably not a perfect
solution but it has shown useful results in both rats and humans (9, 14).
We have also thought about how freezing the samples might influence the
experimental results. To learn more about these potential effects, we would need
to perform multiple experiments comparing fresh and previously frozen samples.
This is difficult for our group because we don’t normally have enough
experienced scientists on hand to process the samples and to run the
mechanical experiments at the same time. It is particularly hard to run
mechanical experiments on tissue obtained from transplants since these
procedures normally take place outside normal working hours.

Recommendations
We have gained a great deal of practical experience since we started this
protocol in 2008. This section lists a few ideas and concepts that groups who are
considering starting their own protocols may wish to consider.
Develop positive relationships with your IRB and biosafety teams


We spoke to members of our IRB before we started writing our protocol
so that we could gain from their experience and advice. We also initiated
interactions with our biosafety advisors rather than waiting until our labs
were inspected. This helped us to develop protocols that are good for our
patients, our institution, and the researchers who perform the
experiments.

Interact with patients and seek their opinions


It is important that patients understand how their samples will be used
and what our research is trying to achieve. We try to meet regularly with
patients and make sure that they support our goals. The VAD and
Transplant Support Group at our institution provides an ideal forum for
these interactions.

Identify key personnel who are responsible for specific tasks


Rather than taking turns on each aspect of the protocol, we ask key
personnel to run specific components. For example, a transplant
coordinator consents each patient who will be listed for a heart transplant,
a scientist manages the inventory, and a faculty member collates clinical
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data from the medical records. We have found that this helps to maintain
consistency and allows team members to specialize in specific areas.
Simplify communication


We provide a single telephone number that the operating room can call
when cardiac tissue might become available. This number is associated
with a single cell phone that the scientists take turns carrying. An
alternative would be to use a forwarding system (such as Google Voice)
that sends a call to multiple phones. On balance, our team prefers to use
a dedicated phone rather than linking their personal cellphones to the
tissue procurement process.

Do not hoard samples


Patients do not donate their cardiac tissue so that it can be stored in a
freezer. Instead, they hope that their samples might help other people
from having to receive heart transplants or ventricular assist devices. We
try to share any samples that we do not need for our own experiments
with other research groups. Our goal is to work together to accelerate
research focusing on advanced heart failure.
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